Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 1
2003 2
2004 3
2005 5
2006 5
2007 5
2008 10
2009 16
2010 7
2011 10
2012 17
2013 11
2014 17
2015 14
2016 17
2017 15
2018 16
2019 9
2020 13
2021 21
2022 13
2023 5
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Results by year

Filters applied: . Clear all
Page 1
Degarelix acetate for the treatment of prostate cancer.
Klotz L. Klotz L. Drugs Today (Barc). 2009 Oct;45(10):725-30. Drugs Today (Barc). 2009. PMID: 20069136 Review.
New strategies are focusing on avoidance of the undesirable effects of testosterone surges or flares associated with the initial stages of gonadotropin-releasing hormone (GnRH) agonists and the significant histamine-mediated side effects that can be associated with GnRH antagonis …
New strategies are focusing on avoidance of the undesirable effects of testosterone surges or flares associated with the initial stages of g …
Degarelix.
Frampton JE, Lyseng-Williamson KA. Frampton JE, et al. Drugs. 2009 Oct 1;69(14):1967-76. doi: 10.2165/10484080-000000000-00000. Drugs. 2009. PMID: 19747011
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, Melloni C, Goodman SG, Evans CP, Nilsson J, Bhatt DL, Clarke NW, Olesen TK, Doyle-Olsen BT, Kristensen H, Arney L, Roe MT, Alexander JH; PRONOUNCE Study Investigators. Lopes RD, et al. Circulation. 2021 Oct 19;144(16):1295-1307. doi: 10.1161/CIRCULATIONAHA.121.056810. Epub 2021 Aug 30. Circulation. 2021. PMID: 34459214 Free PMC article. Clinical Trial.
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
Devos G, Tosco L, Baldewijns M, Gevaert T, Goffin K, Petit V, Mai C, Laenen A, Raskin Y, Van Haute C, Goeman L, De Meerleer G, Berghen C, Devlies W, Claessens F, Van Poppel H, Everaerts W, Joniau S. Devos G, et al. Eur Urol. 2023 Jun;83(6):508-518. doi: 10.1016/j.eururo.2022.09.009. Epub 2022 Sep 24. Eur Urol. 2023. PMID: 36167599 Clinical Trial.
Degarelix for treating advanced hormone-sensitive prostate cancer.
Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, Blümle A, Schmucker C, Mayer B, Kunath F. Zengerling F, et al. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD012548. doi: 10.1002/14651858.CD012548.pub2. Cochrane Database Syst Rev. 2021. PMID: 34350976 Free PMC article. Review.
Questionable oncologic benefits of degarelix.
Secin FP. Secin FP. Urol Oncol. 2016 Oct;34(10):423-6. doi: 10.1016/j.urolonc.2016.05.029. Epub 2016 Jun 28. Urol Oncol. 2016. PMID: 27364704 Review.
Degarelix for prostate cancer.
Doehn C, Sommerauer M, Jocham D. Doehn C, et al. Expert Opin Investig Drugs. 2009 Jun;18(6):851-60. doi: 10.1517/13543780902954713. Expert Opin Investig Drugs. 2009. PMID: 19453267 Review.
210 results